Zivo Bioscience, Inc. Quarterly Common Stock, Shares Authorized from Q4 2010 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Zivo Bioscience, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2010 to Q2 2024.
  • Zivo Bioscience, Inc. Common Stock, Shares Authorized for the quarter ending June 30, 2024 was 25M shares, a 83.3% decline year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 25M -125M -83.3% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 25M -125M -83.3% Mar 31, 2024 10-Q 2024-05-13
Q4 2023 25M 0 0% Dec 31, 2023 10-Q 2024-08-14
Q3 2023 25M -125M -83.3% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 150M 0 0% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 150M 0 0% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 25M -125M -83.3% Dec 31, 2022 10-K 2024-03-15
Q3 2022 150M 0 0% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 150M 0 0% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 150M -1.05B -87.5% Mar 31, 2022 10-Q 2022-05-13
Q4 2021 150M -1.05B -87.5% Dec 31, 2021 10-K 2023-03-14
Q3 2021 150M -1.05B -87.5% Sep 30, 2021 10-Q/A 2022-04-21
Q2 2021 150M -1.05B -87.5% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 1.2B 0 0% Mar 31, 2021 10-Q 2021-05-17
Q4 2020 1.2B 0 0% Dec 31, 2020 10-K 2022-04-22
Q3 2020 1.2B 0 0% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 1.2B 0 0% Jun 30, 2020 10-Q 2020-08-13
Q1 2020 1.2B 0 0% Mar 31, 2020 10-Q 2020-05-11
Q4 2019 1.2B +500M +71.4% Dec 31, 2019 10-K 2021-02-25
Q3 2019 1.2B +500M +71.4% Sep 30, 2019 10-Q 2019-10-28
Q2 2019 1.2B +500M +71.4% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 1.2B +500M +71.4% Mar 31, 2019 10-Q 2019-05-13
Q4 2018 700M 0 0% Dec 31, 2018 10-K 2020-03-26
Q3 2018 700M +250M +55.6% Sep 30, 2018 10-Q 2018-11-14
Q2 2018 700M +250M +55.6% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 700M +250M +55.6% Mar 31, 2018 10-Q 2018-04-23
Q4 2017 700M 0 0% Dec 31, 2017 10-K 2019-02-12
Q3 2017 450M +150M +50% Sep 30, 2017 10-Q 2017-10-19
Q2 2017 450M +150M +50% Jun 30, 2017 10-Q 2017-08-11
Q1 2017 450M +150M +50% Mar 31, 2017 10-Q 2017-05-12
Q4 2016 700M +250M +55.6% Dec 31, 2016 10-K 2018-02-21
Q3 2016 300M Sep 30, 2016 10-Q 2016-11-14
Q2 2016 300M 0 0% Jun 30, 2016 10-Q 2016-08-12
Q1 2016 300M +100M +50% Mar 31, 2016 10-Q 2016-05-13
Q4 2015 450M +150M +50% Dec 31, 2015 10-K 2017-03-31
Q2 2015 300M +100M +50% Jun 30, 2015 10-Q 2015-08-13
Q1 2015 200M 0 0% Mar 31, 2015 10-Q 2015-05-13
Q4 2014 300M +100M +50% Dec 31, 2014 10-K 2016-03-29
Q3 2014 200M 0 0% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 200M 0 0% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 200M 0 0% Mar 31, 2014 10-Q 2014-05-14
Q4 2013 200M 0 0% Dec 31, 2013 10-K 2015-04-06
Q3 2013 200M 0 0% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 200M +50M +33.3% Jun 30, 2013 10-Q 2013-08-13
Q1 2013 200M +50M +33.3% Mar 31, 2013 10-Q 2013-05-06
Q4 2012 200M 0 0% Dec 31, 2012 10-K 2014-03-31
Q3 2012 200M +50M +33.3% Sep 30, 2012 10-Q/A 2012-11-19
Q2 2012 150M 0 0% Jun 30, 2012 10-Q/A 2012-08-31
Q1 2012 150M Mar 31, 2012 10-Q 2012-05-15
Q4 2011 200M +50M +33.3% Dec 31, 2011 10-K 2013-03-25
Q3 2011 150M Sep 30, 2011 10-Q 2011-11-21
Q2 2011 150M Jun 30, 2011 10-Q/A 2011-09-13
Q4 2010 150M Dec 31, 2010 10-K 2012-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.